Sanofi unveils iGlarLixi drug results
A combination insulin/GLP-1 agonist drug has shown greater efficacy in controlling type 2 diabetes.
The results of the Sanofi drug iGlarLixi, formerly known as LixiLan, were unveiled at the American Diabetes Association annual meeting in New Orleans.
The combined product – based on the ingredients in Lantus (insulin glargine) and recently-approved Lyxumia (lixisenatide) – was found to be more effective at controlling blood glucose in type 2 diabetics compared to either drug used alone.
The findings come as iGlarLixi approaches an FDA decision on approval in August this year.
The drug is also under review with the European Medicines Agency (EMA) with a decision due next year.
Dr Mike Baxter, interim medical head of Sanofi Diabetes UK, said: “These latest studies reflect Sanofi’s ongoing commitment to innovative approaches in developing medicines that are intended to help patients manage their condition and potentially gain better control of their diabetes.
“We are continuing to work with the EMA as they complete their review and look forward to receiving their decision.”
If approved it will compete directly with Novo Nordisk’s IDeglira/Xultophy (insulin degludec and liraglutide), which is already on sale in Europe and due for a US FDA decision in September.
The LixiLan-O trial compared the once-daily combination injection with either lixisenatide or insulin glargine over a 30-week period in people with type 2 diabetes whose blood sugar was not adequately controlled with metformin, with or without an additional oral antidiabetic drug.